Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 335

1.

Real-time monitoring of Pseudomonas aeruginosa biofilm formation on endotracheal tubes in vitro.

Pericolini E, Colombari B, Ferretti G, Iseppi R, Ardizzoni A, Girardis M, Sala A, Peppoloni S, Blasi E.

BMC Microbiol. 2018 Aug 14;18(1):84. doi: 10.1186/s12866-018-1224-6.

2.

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.

Di Nunno V, De Luca E, Buttigliero C, Tucci M, Vignani F, Gatto L, Zichi C, Ardizzoni A, Di Maio M, Massari F.

Crit Rev Oncol Hematol. 2018 Sep;129:124-132. doi: 10.1016/j.critrevonc.2018.07.004. Epub 2018 Jul 19. Review.

PMID:
30097230
3.

Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma.

Comito F, Ambrosini V, Sperandi F, Melotti B, Ardizzoni A.

Anticancer Drugs. 2018 Aug 7. doi: 10.1097/CAD.0000000000000689. [Epub ahead of print]

PMID:
30095443
4.

Heterotopic auxiliary segment 2-3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases.

Ravaioli M, Fallani G, Cescon M, Prosperi E, De Pace V, Siniscalchi A, Sangiorgi G, Ferracin M, Ardizzoni A, Morelli MC, Garajová I.

Surgery. 2018 Jul 2. pii: S0039-6060(18)30267-8. doi: 10.1016/j.surg.2018.05.021. [Epub ahead of print] No abstract available.

PMID:
30041968
5.

A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.

Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F.

Anticancer Drugs. 2018 Jun 18. doi: 10.1097/CAD.0000000000000663. [Epub ahead of print]

PMID:
29916898
6.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Jun 14. doi: 10.1001/jamaoncol.2018.0775. [Epub ahead of print]

PMID:
29902295
7.

Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.

Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M.

Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175.

PMID:
29882691
8.

Is the door open to further investigation with antiangiogenesis in SCLC?

Tiseo M, Boni L, Ardizzoni A.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1127-S1128. doi: 10.21037/jtd.2018.03.87. No abstract available.

9.

Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma.

Di Nunno V, Mollica V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F.

Anticancer Drugs. 2018 Aug;29(7):710-715. doi: 10.1097/CAD.0000000000000644.

PMID:
29846249
10.

Immune-mediated cholangitis: is it always nivolumab's fault?

Gelsomino F, Vitale G, Ardizzoni A.

Cancer Immunol Immunother. 2018 Aug;67(8):1325-1327. doi: 10.1007/s00262-018-2159-3. Epub 2018 Apr 5. No abstract available.

PMID:
29623342
11.

Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?

Dall'Olio FG, Brocchi S, Massucci M, Sperandi F, Melotti B, Ardizzoni A.

Eur J Cancer. 2018 May;95:127-129. doi: 10.1016/j.ejca.2018.02.020. Epub 2018 Mar 21. No abstract available.

PMID:
29573943
12.

Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.

Cinausero M, Rihawi K, Sperandi F, Melotti B, Ardizzoni A.

J Thorac Dis. 2018 Jan;10(Suppl 2):S304-S310. doi: 10.21037/jtd.2017.10.19. Review.

13.

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.

Ferrarini A, Forcato C, Buson G, Tononi P, Del Monaco V, Terracciano M, Bolognesi C, Fontana F, Medoro G, Neves R, Möhlendick B, Rihawi K, Ardizzoni A, Sumanasuriya S, Flohr P, Lambros M, de Bono J, Stoecklein NH, Manaresi N.

PLoS One. 2018 Mar 1;13(3):e0193689. doi: 10.1371/journal.pone.0193689. eCollection 2018.

14.

Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.

Rihawi K, Cinausero M, Fiorentino M, Salvagni S, Brocchi S, Ardizzoni A.

J Thorac Oncol. 2018 Mar;13(3):e41-e43. doi: 10.1016/j.jtho.2017.10.024. No abstract available.

PMID:
29472059
15.

Circulating tumor cells in genitourinary tumors.

Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R, Ardizzoni A.

Ther Adv Urol. 2017 Nov 22;10(2):65-77. doi: 10.1177/1756287217742564. eCollection 2018 Feb. Review.

16.

Immune checkpoint inhibitors for metastatic bladder cancer.

Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A.

Cancer Treat Rev. 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31. Review.

PMID:
29407369
17.

Genomic and Phenotypic Variation in Morphogenetic Networks of Two Candida albicans Isolates Subtends Their Different Pathogenic Potential.

Cavalieri D, Di Paola M, Rizzetto L, Tocci N, De Filippo C, Lionetti P, Ardizzoni A, Colombari B, Paulone S, Gut IG, Berná L, Gut M, Blanc J, Kapushesky M, Pericolini E, Blasi E, Peppoloni S.

Front Immunol. 2018 Jan 19;8:1997. doi: 10.3389/fimmu.2017.01997. eCollection 2017.

18.

Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

Ghedini P, Bossert I, Zanoni L, Ceci F, Graziani T, Castellucci P, Ambrosini V, Massari F, Nobili E, Melotti B, Musto A, Zoboli S, Antunovic L, Kirienko M, Chiti A, Mosconi C, Ardizzoni A, Golfieri R, Fanti S, Nanni C.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):751-758. doi: 10.1007/s00259-017-3888-9. Epub 2017 Nov 30.

PMID:
29192364
19.

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.

Fumarola C, Cretella D, La Monica S, Bonelli MA, Alfieri R, Caffarra C, Quaini F, Madeddu D, Falco A, Cavazzoni A, Digiacomo G, Mazzaschi G, Vivo V, Barocelli E, Tiseo M, Petronini PG, Ardizzoni A.

Oncotarget. 2017 Jul 17;8(54):91841-91859. doi: 10.18632/oncotarget.19279. eCollection 2017 Nov 3.

20.
21.

Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?

Gelsomino F, Fiorentino M, Zompatori M, Poerio A, Melotti B, Sperandi F, Gargiulo M, Borghi C, Ardizzoni A.

Ann Oncol. 2018 Jan 1;29(1):284-286. doi: 10.1093/annonc/mdx718. No abstract available.

PMID:
29106493
22.

Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.

Mazzaschi G, Madeddu D, Falco A, Bocchialini G, Goldoni M, Sogni F, Armani G, Lagrasta CA, Lorusso B, Mangiaracina C, Vilella R, Frati C, Alfieri R, Ampollini L, Veneziani M, Silini EM, Ardizzoni A, Urbanek K, Aversa F, Quaini F, Tiseo M.

Clin Cancer Res. 2018 Jan 15;24(2):407-419. doi: 10.1158/1078-0432.CCR-17-2156. Epub 2017 Oct 26.

PMID:
29074606
23.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M-Positive Non-Small Cell Lung Adenocarcinoma.

Dall'Olio FG, Ruatta C, Melotti B, Sperandi F, Ciardella AP, Ardizzoni A.

J Thorac Oncol. 2017 Oct;12(10):e165-e167. doi: 10.1016/j.jtho.2017.06.001. No abstract available.

PMID:
28939150
24.

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN.

Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E.

Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087. eCollection 2017 Aug 8.

25.

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.

Rihawi K, Gelsomino F, Sperandi F, Melotti B, Fiorentino M, Casolari L, Ardizzoni A.

Ther Adv Respir Dis. 2017 Sep;11(9):353-373. doi: 10.1177/1753465817725486. Epub 2017 Aug 17. Review.

26.

ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).

Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A.

J Thorac Oncol. 2017 Sep;12(9):1357-1367. doi: 10.1016/j.jtho.2017.07.005. Epub 2017 Jul 17.

PMID:
28729021
27.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F.

Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. Review.

28.

The synthetic killer peptide KP impairs Candida albicans biofilm in vitro.

Paulone S, Ardizzoni A, Tavanti A, Piccinelli S, Rizzato C, Lupetti A, Colombari B, Pericolini E, Polonelli L, Magliani W, Conti S, Posteraro B, Cermelli C, Blasi E, Peppoloni S.

PLoS One. 2017 Jul 13;12(7):e0181278. doi: 10.1371/journal.pone.0181278. eCollection 2017.

29.

The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome.

Massari F, Ciccarese C, Hes O, Michal M, Caliò A, Fiorentino M, Giunchi F, D'Amuri A, Sanguedolce F, Sabbatini R, Guida A, Ardizzoni A, Porta C, Iacovelli R, Tortora G, Cima L, Ortega C, Lapini A, Martignoni G, Brunelli M.

Pathol Oncol Res. 2018 Jul;24(3):447-456. doi: 10.1007/s12253-017-0271-x. Epub 2017 Jul 10. Review.

PMID:
28695322
30.

A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.

Gelsomino F, Vitale G, Ardizzoni A.

Invest New Drugs. 2018 Feb;36(1):144-146. doi: 10.1007/s10637-017-0484-6. Epub 2017 Jun 20.

PMID:
28631096
31.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

32.

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G.

Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

PMID:
28572027
33.

Candida albicans survival, growth and biofilm formation are differently affected by mouthwashes: an in vitro study.

Paulone S, Malavasi G, Ardizzoni A, Orsi CF, Peppoloni S, Neglia RG, Blasi E.

New Microbiol. 2017 Jan;40(1):45-52.

34.

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial.

Tiseo M, Boni L, Ambrosio F, Camerini A, Baldini E, Cinieri S, Brighenti M, Zanelli F, Defraia E, Chiari R, Dazzi C, Tibaldi C, Turolla GM, D'Alessandro V, Zilembo N, Trolese AR, Grossi F, Riccardi F, Ardizzoni A.

J Clin Oncol. 2017 Apr 20;35(12):1281-1287. doi: 10.1200/JCO.2016.69.4844. Epub 2017 Jan 30.

PMID:
28135143
35.

Metachronous solitary metastasis to the thyroid gland from squamous cell carcinoma of the lung: a case report and literature review.

Gelsomino F, Lamberti G, Ambrosini V, Sperandi F, Agosti R, Morganti AG, Ardizzoni A.

Tumori. 2017 Nov 15;103(Suppl. 1):e12-e15. doi: 10.5301/tj.5000605. Review.

PMID:
28127743
36.

Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury.

Gelsomino F, Vitale G, D'Errico A, Bertuzzi C, Andreone P, Ardizzoni A.

Ann Oncol. 2017 Mar 1;28(3):671-672. doi: 10.1093/annonc/mdw649. No abstract available.

PMID:
27993797
37.

Apoptosis and inflammatory response in human astrocytes are induced by a transmissible cytotoxic agent of neurological origin.

Beretti F, Ardizzoni A, Cermelli C, Guida M, Maraldi T, Pietrosemoli P, Paulone S, De Pol A, Blasi E, Portolani M.

New Microbiol. 2017 Jan;40(1):27-32. Epub 2016 Nov 7.

38.

Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study.

Giunchi F, Degiovanni A, Daddi N, Trisolini R, Dell'Amore A, Agostinelli C, Ardizzoni A, Fiorentino M.

Appl Immunohistochem Mol Morphol. 2018 Aug;26(7):489-494. doi: 10.1097/PAI.0000000000000458.

PMID:
27801735
39.

Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.

Fiorentino M, Gruppioni E, Massari F, Giunchi F, Altimari A, Ciccarese C, Bimbatti D, Scarpa A, Iacovelli R, Porta C, Virinder S, Tortora G, Artibani W, Schiavina R, Ardizzoni A, Brunelli M, Knuutila S, Martignoni G.

Oncotarget. 2017 Jan 31;8(5):7328-7335. doi: 10.18632/oncotarget.12551.

40.

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.

Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D'Alessandro V, de Marinis F, Barbera S, Caroti C, Favaretto A, Cortinovis D, Morrica B, Tixi L, Ceschia T, Parisi S, Ricardi U, Grimaldi A, Loreggian L, Navarria P, Huber RM, Belani C, Brunsvig PF, Scagliotti GV, Scolaro T.

Lung Cancer. 2016 Oct;100:30-37. doi: 10.1016/j.lungcan.2016.07.026. Epub 2016 Jul 27.

41.

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study.

Picardi V, Deodato F, Guido A, Giaccherini L, Macchia G, Gambacorta MA, Arcelli A, Farioli A, Cellini F, Cuicchi D, DI Fabio F, Poggioli G, Ardizzoni A, Frezza G, Cilla S, Caravatta L, Valentini V, Fuccio L, Morganti AG.

Anticancer Res. 2016 Aug;36(8):4081-7.

PMID:
27466517
42.

Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: A Phase II Study.

Picardi V, Macchia G, Guido A, Giaccherini L, Deodato F, Farioli A, Cilla S, Compagnone G, Ardizzoni A, Cuicchi D, Gambacorta MA, Cellini F, Frezza G, Poggioli G, Valentini V, Fuccio L, Morganti AG.

Clin Colorectal Cancer. 2017 Mar;16(1):16-22. doi: 10.1016/j.clcc.2016.06.004. Epub 2016 Jun 23.

PMID:
27435759
43.

MET DNA Alterations in NSCLC-Letter.

Mengoli MC, Bertolini F, Tiseo M, Barbieri F, Fiorentino M, Ardizzoni A, Rossi G.

Clin Cancer Res. 2016 Jul 15;22(14):3697-8. doi: 10.1158/1078-0432.CCR-16-0351. No abstract available.

44.

Human biliary tree stem/progenitor cells immunomodulation: Role of hepatocyte growth factor.

Maraldi T, Guida M, Beretti F, Resca E, Carpino G, Cardinale V, Gentile R, Ardizzoni A, Murgia A, Alvaro D, Gaudio E, De Pol A.

Hepatol Res. 2017 Apr;47(5):465-479. doi: 10.1111/hepr.12772. Epub 2016 Aug 16.

PMID:
27381820
45.

Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.

Musolino A, Naldi N, Dieci MV, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali DG, Piacentini F, Ambroggi M, Cagossi K, Gianni L, Sarti S, Bisagni G, Ardizzoni A, Conte PF, Guarneri V.

Pharmacogenomics J. 2016 Oct;16(5):472-7. doi: 10.1038/tpj.2016.51. Epub 2016 Jul 5.

PMID:
27378608
46.

(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1971-9. doi: 10.1007/s00259-016-3428-z. Epub 2016 Jun 8.

PMID:
27277279
47.

Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study.

Picardi V, Deodato F, Guido A, Giaccherini L, Macchia G, Frazzoni L, Farioli A, Cuicchi D, Cilla S, Cellini F, Uddin AF, Gambacorta MA, Buwenge M, Ardizzoni A, Poggioli G, Valentini V, Fuccio L, Morganti AG.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1184-90. doi: 10.1016/j.ijrobp.2016.03.010. Epub 2016 Mar 19.

PMID:
27215449
48.

193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment.

Felip E, Van Meerbeeck J, Wolf J, Ardizzoni A, Li A, Srinivasan S, Popat S.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S141. doi: 10.1016/S1556-0864(16)30302-1. Epub 2016 Apr 15. No abstract available.

49.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC.

Gelsomino F, Ambrosini V, Melotti B, Sperandi F, Ardizzoni A.

J Thorac Oncol. 2016 Aug;11(8):e99-e101. doi: 10.1016/j.jtho.2016.04.002. Epub 2016 Apr 12. No abstract available.

50.

Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction.

van Kruijsdijk RC, Visseren FL, Boni L, Groen HJ, Dingemans AM, Aerts JG, van der Graaf Y, Ardizzoni A, Smit EF.

Ann Oncol. 2016 Jul;27(7):1280-6. doi: 10.1093/annonc/mdw154. Epub 2016 Apr 6.

PMID:
27052652

Supplemental Content

Loading ...
Support Center